GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » EV-to-FCF

Greenyn Biotechnology Co (ROCO:6846) EV-to-FCF : 50.86 (As of May. 16, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Greenyn Biotechnology Co's Enterprise Value is NT$1,809.5 Mil. Greenyn Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was NT$35.6 Mil. Therefore, Greenyn Biotechnology Co's EV-to-FCF for today is 50.86.

The historical rank and industry rank for Greenyn Biotechnology Co's EV-to-FCF or its related term are showing as below:

ROCO:6846' s EV-to-FCF Range Over the Past 10 Years
Min: 8.12   Med: 11.58   Max: 56.98
Current: 47.94

During the past 5 years, the highest EV-to-FCF of Greenyn Biotechnology Co was 56.98. The lowest was 8.12. And the median was 11.58.

ROCO:6846's EV-to-FCF is ranked worse than
78.48% of 381 companies
in the Biotechnology industry
Industry Median: 7.56 vs ROCO:6846: 47.94

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Greenyn Biotechnology Co's stock price is NT$78.90. Greenyn Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was NT$5.300. Therefore, Greenyn Biotechnology Co's PE Ratio for today is 14.89.


Greenyn Biotechnology Co EV-to-FCF Historical Data

The historical data trend for Greenyn Biotechnology Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co EV-to-FCF Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - 8.08 47.24

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.80 16.19 11.79 47.24 -

Competitive Comparison of Greenyn Biotechnology Co's EV-to-FCF

For the Biotechnology subindustry, Greenyn Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's EV-to-FCF falls into.



Greenyn Biotechnology Co EV-to-FCF Calculation

Greenyn Biotechnology Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1809.465/35.577
=50.86

Greenyn Biotechnology Co's current Enterprise Value is NT$1,809.5 Mil.
Greenyn Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$35.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Greenyn Biotechnology Co  (ROCO:6846) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Greenyn Biotechnology Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=78.90/5.300
=14.89

Greenyn Biotechnology Co's share price for today is NT$78.90.
Greenyn Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$5.300.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Greenyn Biotechnology Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines